In the absence of Coolstocks making a prediction based on this news I'll have a go instead.
Start TT-034 trial late Nov: Allowing for IND, recruit, patient screening etc.
Collect first cohort transfection data mid Dec 2013.
Interim safety/transfection data published mid Jan 2014: Allowing for collection/analysis, silly season and publication.
Safety data and transfection rates equal to or better than NHP model for equivalent dose.
Data extrapolation based on NHP model points to success of higher doses.
Share price starts take off after data publication and reaches $1.35 (5.4c in the old money) by end of Feb 2014.
How did I go Cool?
movement on the hcv front, page-3
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)